Virtual Library

Start Your Search

Hiroto Tanaka

Author of

  • +

    P1.14 - Thymoma/Other Thoracic Malignancies (Not CME Accredited Session) (ID 946)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
    • +

      P1.14-26 - Long Term Outcome and Clinicopathological Features of Thymic Carcinoma - A Retrospective Study of 25 Cases at a Single Institution (ID 12371)

      16:45 - 18:00  |  Presenting Author(s): Hiroto Tanaka

      • Abstract
      • Slides


      Thymic carcinoma is a rare and invasive mediastinal tumor and the optimal treatment is not well defined currently. According to the Clinical report from Japanese Association for Research on the Thymus in 2015, surgical resection is the mainstream of treatment, and the 5-year overall survival was 61%. The patient with complete resection with a 5-year survival of 89%, 68%, 60% for stages I, II & III and IV, respectively. In order to clarify the long-term outcome and prognostic indicators in our facilities, we reviewed our institutional experience with cases of surgical resection for thymic carcinoma.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      A single-institution retrospective study of patients operated for thymic carcinoma. Between 1998 and 2017, 25 patients with thymic carcinoma underwent surgical resection, and their clinical and pathological data were retrospectively reviewed. Overall survival (OS) rates were compared using a log- rank test and Survival curves were plotted using the Kaplan–Meier method.

      4c3880bb027f159e801041b1021e88e8 Result

      Twenty-five patients underwent surgery for thymic carcinoma. The IASLC/ITMIG thymic epithelial tumors Stage according to the 8thedition of the TNM classification was I in 9 patients, II in 6, III in 5, IV in 5. A complete resection was achieved in ten patients (40%) that were no recurrence and death in the follow-up period. There was no fetal complication and no postoperative mortality. Adjuvant radiotherapy and/or chemotherapy was offered to 22 patients. The median follow-up period was 37 months. The 5-year overall survival rate for all the patients were 78.2%. Patients who underwent an incomplete resection had a significantly worse survival as compared to those with complete resection in univariate analyses (p < 0.01).

      8eea62084ca7e541d918e823422bd82e Conclusion

      Our result indicated that complete resection could impact the overall survival of patients with thymic carcinoma after surgical resection.


      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.